Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.93 EUR
Change Today -0.049 / -5.02%
Volume 0.0
LX3 On Other Exchanges
LX3 is not on other exchanges.
As of 11:09 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LX3) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/14 - €1.35
52 Week Low
12/16/14 - €0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LX3) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LX3) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase II clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound that has completed Phase II clinical trials to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound that has completed Phase I clinical trials for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Ipsen Pharma SAS; and drug discovery alliance with Bristol-Myers Squibb Company and Genentech, Inc. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

106 Employees
Last Reported Date: 03/12/15
Founded in 1995

lexicon pharmaceuticals inc (LX3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $431.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $534.5K
Executive Vice President of CMC and Supply Op...
Total Annual Compensation: $457.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $445.4K
Compensation as of Fiscal Year 2014.

lexicon pharmaceuticals inc (LX3) Key Developments

Lexicon Pharmaceuticals, Inc. Announces Amendment to the Amended and Restated Certificate of Incorporation

The annual meeting of stockholders of Lexicon Pharmaceuticals, Inc. held on April 23, 2015, has approved an amendment to the amended and restated certificate of incorporation to effect, at the discretion of company's board of directors, a reverse split of company's common stock and a reduction in the number of authorized shares of common stock.

Lexicon Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:40 AM

Lexicon Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Lexicon Pharmaceuticals, Inc. Announces First Patient Screened in Pivotal Phase 3 Clinical Trial of Sotagliflozin

Lexicon Pharmaceuticals, Inc. announced that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin for type 1 diabetes. Lexicon will be conducting two pivotal Phase 3 clinical trials of sotagliflozin, one in North America and another primarily in Europe. Each pivotal trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of sotagliflozin in adult patients with type 1 diabetes. Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested along with placebo. The primary efficacy endpoint under evaluation will be reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7%, reduction in meal-time, or bolus, insulin use and weight loss.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LX3:GR €0.93 EUR -0.049

LX3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.61 USD +0.12
Boston Scientific Corp $17.75 USD -0.23
CR Bard Inc $170.38 USD -1.24
Johnson & Johnson $100.24 USD -0.34
Medtronic PLC $75.85 USD -0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation LX3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.6x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at